Antengene, WuXi Biologics Ink Innovative Oncology R&D Alliance

Antengene Corp., a biopharmaceutical company dedicated to developing first-in-class therapeutics in hematology and oncology, and WuXi Biologics, have signed a strategic Memorandum of Understanding (MoU) for the development and production of novel drugs, and to jointly promote R&D of innovative oncology therapies.

"We are very glad to launch a strategic cooperation with WuXi Biologics. This cooperation is a timely decision. WuXi Biologics has first-class biopharmaceutical capabilities and could empower us with advanced technology," said Dr. Jay Mei, Founder, Chairman and CEO of Antengene. "At present, Antengene has carried out a comprehensive layout for the research and development of innovative cancer medicines, and continues to promote the science-oriented R&D of anti-tumor drugs such as small molecule drugs, monoclonal drugs and bispecific antibody drugs. We are looking forward to enhancing the quality of research and development and leveraging complementary strengths of both companies in order to ultimately benefit a wider range of cancer patients."

Dr. Chris Chen, CEO of WuXi Biologics, said, "We are pleased to establish a strategic cooperation with Antengene. Through our diversified and integrated biologics technology platform, WuXi Biologics will continue to empower Antengene to accelerate the R&D process of innovative oncology therapies. We look forward to working together to achieve a win-win situation based on our capabilities and advantages and make positive contribution to the health and wellness of patients in China and the world."